Structure of β-(1→3)/(1→6)-glucans, Dectin-1 recognition, and cellular trained-immunity models; human studies of yeast and mushroom products, safety, and limits on extrapolating results.
β-glucan is not one molecule with a fixed effect. Fungal cell walls contain glucose regions linked by β-(1→3) bonds, often with β-(1→6) branches, but branching frequency, chain length, molecular mass, solubility, aggregation, and extraction differ by species, fungal tissue, and product. These properties affect contact with innate immune receptors, but cannot by themselves predict the clinical effect of a particular supplement.
Dectin-1 (CLEC7A) recognizes accessible β-glucan structures on myeloid cells. For particles, spatial organization matters alongside chemical linkages: receptor clustering and a phagocytic synapse can direct signals through Src kinases, Syk, and the CARD9–BCL10–MALT1 adaptor complex. In cell and animal models, selected β-glucan stimuli can also induce a “trained” phenotype in monocytes and macrophages: after a resting period, they respond differently to a later, even unrelated, stimulus. This is functional memory of innate cells in the laboratory, not proof that taking a mushroom extract prevents infection or treats cancer.
Human studies tested different substances and outcomes. A small oral β-glucan study did not find measurable enhancement of the innate response in blood; a trial of one yeast product reported fewer symptomatic colds in its per-protocol analysis, but those results cannot be attributed to reishi or maitake. A randomized study of purified reishi β-glucan measured laboratory immune markers, not disease incidence. Oncology studies concern separate extracts and pharmaceutical polysaccharides combined with standard therapy, and do not establish that products are interchangeable.
The fungal cell wall is a composite scaffold. It contains glucans with different linkages, chitin, proteins, and glycoproteins; proportions depend on species, growth stage, fruiting body or mycelium, and culture conditions. A host-cell receptor encounters this organized wall or its particles, not necessarily a purified, uniform polymer. The effects of whole mushroom, powder, water extract, alcohol extract, and purified polysaccharide fraction therefore cannot be collapsed into one “mushroom β-glucan.”
In β-glucan, D-glucose monomers are joined by glycosidic bonds. Many fungal polymers have a β-(1→3) backbone with β-(1→6) side branches at varying positions. Structural studies of particular Ganoderma lucidum spore fractions, for example, have described both a highly branched, water-soluble glucan and a more complex glucan with a different backbone and branch architecture. These findings apply to the isolated materials studied; they show why one preparation’s structure cannot be treated as a universal formula for reishi, maitake, or all commercial extracts. Some fractions also contain protein or heterosaccharides.
Chemical structure is determined with complementary methods. Methylation and analysis of hydrolysis products help identify substitution positions; NMR reveals bond types and local sugar environments; chromatography and light scattering estimate molecular-size distributions; enzyme assays and mass spectrometry add compositional information. No single measure tells how strongly a preparation activates a receptor or improves human health. A label stating “30% β-glucans,” without the analytical method, distinction between fungal and yeast glucans, or control of the sample matrix, may be inadequate for comparing products.
β-(1→3) and β-(1→6) describe which carbon atoms of neighboring sugars are linked, but do not specify the polymer’s full topology. Branch position and frequency, side-oligosaccharide length, molecular mass, and whether chains remain aggregated all matter. Partial purification may co-extract proteins and other carbohydrates; hydrolysis or alkali treatment can change the original architecture. A structural description should therefore identify the raw material and how it was prepared.
Two mixtures with the same β-glucan mass fraction may differ in polymer-chain length, branch number, molecular mass, aggregation, and solubility. These properties are influenced by the raw material and extraction: hot water, alkali, fermentation, milling, alcohol precipitation, or later purification can change which fraction is retained and how soluble it is. A “triple helix” is a model for the spatial organization of some β-(1→3)-glucans, not a universal required form of all fungal polymers. Solubility and conformation depend on structure and measurement conditions.
Ligand form has functional consequences. Particles, aggregates, and soluble fragments present repeated sugar motifs to multiple receptors in different ways. In Dectin-1 experiments, particles formed a localized membrane contact and initiated a so-called phagocytic synapse; soluble β-glucan could bind, but did not reproduce particle signalling in every respect. This helps explain why results for a purified soluble polymer cannot automatically be transferred to an insoluble yeast product or a fruiting-body extract.
Ganoderma lucidum (reishi) and Grifola frondosa (maitake) are different basidiomycetes, and composition also varies within each species by strain, tissue, cultivation, and processing. Products may use fruiting bodies, mycelium grown on substrate, spore powder, whole-mushroom powder, or extracts standardized to “polysaccharides” or “β-glucans.” Protein, chitin, starchy carrier, and other polysaccharides can affect total-mass measurement and biological response.
The terms D-fraction and MD-fraction refer to commercially or experimentally defined maitake products, not one international pharmacopoeial substance. One fraction’s composition cannot describe every product labelled maitake. Similarly, “GLPS” can refer to different reishi polysaccharide extracts. Interpreting a study requires botanical identification, the mushroom part, extraction method, analytical confirmation of composition, and comparability between the tested and marketed product.
Dectin-1 is a C-type membrane receptor encoded by CLEC7A. Its extracellular lectin-like domain recognizes some β-glucan structures; its short cytoplasmic tail signals through a hemITAM motif. The receptor is found mainly on monocytes, macrophages, dendritic cells, and neutrophils; its abundance and role depend on cell population and tissue state. It recognizes microbial structures; it is not a specific “reishi sensor.”
Ligand accessibility at the surface matters. In some fungi, the outer cell-wall layer partly masks β-glucan; changes in growth, damage, or cell death can expose hidden components to receptors. In studies of Candida albicans, live and heat-killed cells elicited different recognition patterns in human blood cells: in the system used, mannan on live yeast and accessible β-glucan on killed cells contributed differently to the response. This illustrates why contact with whole fungus cannot be reduced to β-glucan content in a purified extract.
The mouse carbohydrate-recognition-domain crystal structure known as PDB 2CL8 was obtained with a short β-glucan oligosaccharide. It provides evidence about possible protein–ligand contacts in that particular crystal system. One structure cannot establish the complete binding mechanism for a long fungal polymer, universal contact residues in the human receptor, clinical affinity of a product, or exact receptor behaviour on living cells. Unsupported affinity constants and lists of “required” contact residues are therefore not given here.
Ligand size and presentation change the scale of the signal. When a cell contacts a particle, Dectin-1 concentrates in the membrane region where receptors come together. The experimental “phagocytic synapse” model shows how contact geometry may limit local access by large phosphatases and sustain phosphorylation of the receptor motif. It is a useful mechanistic model for particle recognition, not a claim that every soluble extract creates the same contact in the human intestine.
After hemITAM phosphorylation, Syk binds the tyrosine site. The signal can then involve PLCγ, PKCδ, and CARD9–BCL10–MALT1, which connects the signal to IKK/NF-κB; MAPK pathways and AP-1 activity may also change. Outcomes depend on cell type and co-stimuli. CARD9 is required for several Dectin-1-dependent responses to fungal structures in experimental models, although details differ among macrophages and dendritic cells.
This cascade should not be drawn as one linear inflammation switch. Syk and associated branches contribute to phagocytosis, cytoskeletal remodelling, and cytokine production, but those outcomes do not necessarily require the same intermediates. Primary macrophage and dendritic-cell populations use CARD9 differently for TNF-α and other mediators. Co-stimulation of Dectin-1 and Toll-like receptors can change the response’s composition and magnitude: cell-wall material contains several potential ligands, not glucan alone.
Phospholipase Cγ and calcium signals can involve calcineurin-dependent transcriptional regulation, including NFAT, while MAPK activates additional transcription factors. Not all cytokine production reduces to NF-κB, and Dectin-1 stimulation does not always produce the same inflammatory profile. Physiological responses balance recognition, phagocytosis, microbial killing, co-receptor signals, and limits on tissue injury.
Dectin-1 does not work alone. Other cell-wall receptors, including TLRs and other lectin receptors, can alter the response profile. Whole microorganisms contain mannans, proteins, lipids, and nucleic acids, so a fungal response cannot be assigned to one glucan without specific control experiments. A study of purified β-glucan and a study of live or killed fungus answer different questions.
Dectin-1 stimulation can affect cytokine programs, phagocytosis, and reactive oxygen species production. The profile includes both pro-inflammatory and regulatory mediators; it is not a constant increase in “immunity.” For IL-1β, transcriptional priming must be distinguished from subsequent inflammasome activation that helps process pro-IL-1β. The required signals and role of NLRP3 depend on the experimental system. An increase in one cytokine in a dish does not predict infection prevention or a more useful immune response. IL1B mRNA is not the same as secreted active IL-1β: maturation and release signals may also be required. Preparations differ in impurities and physical properties that can activate additional receptors or cellular stress. Inflammasome findings should therefore be read alongside the purification method, control ligands, cell type, and functional assay.
Trained immunity is an experimentally described change in the later response of innate cells after an initial exposure. In the classic model, human monocytes contact β-glucan briefly, the stimulus is removed, and the cells undergo a resting period. On restimulation with another agent, some mediators may be produced differently or in greater amounts than in control cells. This differs from antigen-specific memory in T and B lymphocytes: it does not mean that the body recognizes a particular virus or fungus with adaptive-immune precision.
Primary experiments use defined β-glucan concentrations and forms, and culture monocytes under controlled conditions. Medium changes, resting time, differentiation into macrophages, cell survival, and the secondary stimulus all affect the result. The statement “cells responded more strongly a week later” must therefore specify the model; it cannot become a universal duration of supplement action in people. A laboratory protocol generally includes an initial pulse, ligand removal, several days without the primary stimulus, and a secondary challenge such as a bacterial component. Investigators compare the secondary response with an unstimulated control and assess whether differences reflect cell survival or differentiation. This secondary challenge is essential to the definition of “training”: a brief initial cytokine burst alone is not trained immunity. A mouse live-infection experiment also tests host protection, a separate evidence level.
Studies in human monocytes have found changes in histone marks and chromatin accessibility, including activating H3K4me3 and H3K27ac modifications at response-related genes. This is not equivalent to permanent DNA modification or irreversible reprogramming of the whole organism. Because monocytes have limited lifespans, persistence of a functional effect may depend on renewed differentiation, tissue signals, and production of new cells. An epigenetic map shows regulated chromatin regions and their association with gene activity, not the causal effect of every mark. Individual histone modifications vary by gene, donor, and time. Establishing that a particular mark is necessary requires interventions in relevant enzymes or regulatory elements, not merely correlation with increased cytokine secretion. H3K4me3 or H3K27ac findings do not support a vague claim of “rewriting DNA.”
Metabolic studies of β-glucan-trained cells have found increased glycolysis, glucose consumption, and lactate production; Akt–mTOR–HIF-1α participated in specific models. Metabolite use and regulation of inflammatory-response genes also change. This does not mean every mushroom extract causes the same “Warburg effect” or that glycolysis should be increased in people. Metabolic pathways may support protection in one setting and excessive inflammation in another. Glucose consumption, extracellular acidification, and lactate provide complementary metabolic measures, but do not describe the entire cell. Inhibiting Akt, mTOR, or HIF-1α and weakening the trained response supports participation of those pathways in the model; it does not establish a ready-made human treatment target. Metabolism depends on nutrients, oxygen, tissue, and inflammatory context. “Glycolysis instead of mitochondria” is too crude: reprogramming changes pathway fluxes without necessarily switching off oxidative phosphorylation.
A glycolytic shift does not mean the tricarboxylic acid (TCA) cycle is switched off. In a primary human-monocyte model, β-glucan training also changed glutamine metabolism: glutaminase converts glutamine to glutamate, and further conversion of glutamate to α-ketoglutarate (α-KG) replenishes TCA intermediates, a process called glutaminolysis and anaplerotic replenishment. Metabolomic measurements found increases in fumarate, succinate, and malate among trained-cell metabolites. Fumarate is produced in the mitochondrial TCA cycle as succinate is oxidized by succinate dehydrogenase (complex II); it is not a “histone building block,” but a metabolite capable of altering α-KG-dependent enzymes.
Arts and colleagues tested this transition in primary human monocytes: they applied β-glucan for one day, removed it, and rested the cells before restimulation. The glutaminase inhibitor BPTES reduced fumarate production and weakened β-glucan-dependent training in that system; fumarate addition alone reproduced part of the phenotype, whereas malate and succinate did not produce the same result in that experiment. This is causal evidence for a particular cell model, not proof that a mushroom supplement raises fumarate or strengthens protection in a person after ingestion.
The connecting link is the KDM5 histone-demethylase family, which removes methyl groups from lysine 4 of histone H3. These enzymes are α-KG-dependent dioxygenases: α-KG is needed for catalysis, while structurally related metabolites, including fumarate, can inhibit enzyme activity. In the Arts study, β-glucan-trained monocytes had lower measured KDM5 activity on day six, coinciding with high intracellular fumarate; added α-KG partially restored KDM5 activity and weakened the response to restimulation. In corresponding cell measurements, increased H3K4me3 at pro-inflammatory gene promoters is consistent with the mark persisting longer when its removal slows. This concerns methylation of histone H3, not methylation of DNA cytosines; the study did not establish DNA methylation.
This model does not mean that one metabolite explains the full epigenetic profile. β-glucan changes several pathways, and added fumarate reproduced only some training-associated sites and functions. KDM5 directly concerns H3K4 demethylation; H3K27ac changes, involving acetylation of a different histone, cannot be explained solely by KDM5 inhibition. The result should be limited to the specific primary-cell protocol, resting period, and chromatin-mark analysis, not transferred to the whole organism or clinical supplement effects.
A separate research line concerns central trained immunity. After selected β-glucan particles were administered to mice, myeloid progenitor and descendant-cell function in bone marrow changed. This is an important experimental immunology mechanism, but it was shown in specific animal models and conditions. There is no basis to describe it as a proven result of long-term reishi or maitake use in people.
A newer study of whole yeast β-glucan particles further indicates that training depends on particle form and physical organization in the model used. This narrows transferability: the chemical label “β-1,3/1,6-glucan” does not guarantee an equivalent training stimulus from another fraction. The manufacturer, purity, and physical properties of the preparation may be inseparable from the experimental effect.
High-molecular-weight polysaccharides should not be described as automatically entering the blood by the same route as ordinary glucose. Humans do not have a digestive β-glucanase that converts all such polymers into fully absorbable monomers. Some glucans pass through the intestine and may interact with the microbiota; physical particles may contact intestinal lymphoid tissue. Microbial fermentation of some dietary fibres is discussed in the review of dietary fibre and prebiotics, but that does not mean mushroom extracts have the same effects or that fermentation itself provides clinical immune protection. The proportion, size, and fate of such fragments depend on the material and model.
Animal and cell experiments have studied particle uptake by M cells or phagocytes, transport to regional lymph nodes, and macrophage processing. These observations generate hypotheses about interactions between intestinal immunity and β-glucan, but do not prove the sequence “ingestion → uptake of an intact molecule → transport to bone marrow → trained immunity” in humans. A small oral yeast β-glucan study in healthy volunteers found only trace serum levels and did not confirm enhanced measured innate-response markers. Failure to detect a blood concentration does not exclude local intestinal interaction, but it does not establish systemic bioavailability.
Clinical studies cannot be combined just because they use the word “β-glucan.” They tested different sources—yeast, mushroom fruiting bodies, or isolated polysaccharides—particle forms, doses, durations, and endpoints. Changes in immune-cell counts, laboratory cell activity, cold-symptom incidence, tumour response, and overall survival are different outcomes.
In a randomized, open-label pilot study, 15 healthy men received 1,000 mg/day oral β-glucan for seven days or control. β-glucan was barely detectable in serum; the authors found no support for using this specific regimen to enhance innate immune responses in people. The small sample, open design, short period, and specific preparation limit the conclusion, but the negative result matters: a cell-laboratory effect does not guarantee the same effect after ingestion.
In another multicentre, double-blind trial, 162 participants with a history of frequent infections received 900 mg/day of an insoluble yeast β-(1→3)/(1→6)-glucan or placebo for 16 weeks. In the per-protocol analysis, symptomatic colds were 25% fewer in the glucan group (p=0.041). The mean symptom-score difference was 15% and was not statistically significant (p=0.125). This finding concerns one yeast product and a per-protocol analysis; it is not proof that mushroom extracts prevent infection or that trained immunity was induced in participants.
A randomized, double-blind trial of G. lucidum β-glucan enrolled healthy adults; the intervention lasted 84 days and researchers assessed laboratory immune markers, including cell populations, NK-cell cytotoxicity, and serum IgA. It was not a cold-prevention or infection-treatment trial. It also concerned one standardized product and does not establish that any reishi or maitake capsule reproduces the result. Biomarker studies help define next questions, but are not equivalent to confirmed clinical benefit. When a laboratory marker changes after an intervention, questions remain about the size of the difference, whether it persists after use stops, whether it relates to fewer infections, and whether it reproduces in people with other health conditions. These require separate clinical-outcome studies.
The paper describes a daily capsule containing 200 mg of the reishi preparation; analysis found 75.2% β-glucan, so product mass is not automatically pure-polymer mass. Results report 157 randomized participants (80 and 77), with 135 completing the trial (70 and 65), whereas Methods describes 126 enrolled: this internal discrepancy limits confidence in sample reporting. The endpoint table gives NK-cell cytotoxicity as 67.4 ± 12.4% versus 35.8 ± 8.3% (p=0.001). This is a laboratory assay result, not the proportion of infections prevented.
β-glucans in oncology must be separated into dietary mushroom supplements, research extracts, and pharmaceutical preparations. In mouse experiments, selected yeast β-glucan particles enhanced the antitumour effect of some monoclonal antibodies. This is a model of β-glucan interaction with antibody-dependent pathways and host cells, not clinical evidence for taking mushroom supplements alone.
A phase II maitake-extract study in myelodysplastic syndrome was open-label and nonrandomized. It enrolled 21 patients and evaluated 18; patients with low or intermediate-1 risk received the investigational extract at 3 mg/kg twice daily for 12 weeks. Primary measures were neutrophil function and ex vivo reactive oxygen species production, not remission, survival, or prevention of progression to leukaemia. Authors reported changes in some functional markers and asymptomatic eosinophilia in some participants. Small size, no randomized control, and surrogate endpoints do not establish maitake as an antitumour therapy.
Lentinan is a purified pharmaceutical β-(1→3)-glucan from shiitake, studied as an addition to chemotherapy in some countries. In a phase III randomized trial of lentinan plus S-1 for unresectable or recurrent gastric cancer, overall survival did not improve significantly compared with S-1 alone; time to treatment failure was shorter in the combination group. The drug product, standardized dose, patient population, and treatment control are not equivalent to dietary supplements. This does not prove benefit or harm for all mushroom polysaccharides, but shows why preclinical synergy cannot become a clinical promise. The trial randomized 154 patients to S-1 and 155 to S-1 plus lentinan. Median overall survival was 13.8 and 9.9 months, respectively (p=0.208); median time to treatment failure was 4.3 and 2.6 months (p<0.001). The primary overall-survival endpoint did not improve, while time to treatment failure was worse in the combination group. These outcomes concern the specific population and protocol and do not test reishi or maitake supplements.
Short-term tolerability in some studies generally did not show frequent severe reactions, but this does not establish the safety of every species, extract, or long-term regimen. Gastrointestinal symptoms and allergic reactions are possible; risk depends on raw material, contamination, and composition. People with mushroom allergy should avoid products that trigger a reaction. People with immunodeficiency, autoimmune disease, a transplant, or immunosuppressive therapy should especially discuss supplements with their clinician: a proposed effect on immune pathways does not guarantee a desirable response and is not a reason to alter medication.
Immune-interaction data alone do not prove clinically meaningful interactions with every anticoagulant, glucose-lowering medicine, or immunosuppressant. However, extracts may contain many constituents, and human interaction studies are limited. Caution is appropriate with narrow-therapeutic-index medicines, before surgery, during pregnancy, and while breastfeeding. Vitamin C, zinc, or probiotics should not be treated as proven enhancers of mushroom β-glucan; taking them together does not establish pharmacological synergy.
Batch quality is assessed through identification of species and mushroom part, checks for substitutes and adulterants, heavy metals, microbial and pesticide contamination, and reproducible β-glucan analysis. For fungal materials, the method should distinguish β-glucan from α-glucans and carriers, and results should be linked to a specific batch. HPLC/GPC, NMR, molecular-mass distribution, and enzymatic methods suit different research questions, but naming a method does not itself establish clinical efficacy.
Before comparing products, determine whether species, mushroom part, cultivation and extraction methods, solubility, standardization, and particle form match. “Total polysaccharides” is not the same as β-glucan content; different assay kits may produce incomparable values. A marketed fraction name does not guarantee identity with the research material. Independent contaminant testing matters as much as the declared active-component amount.
When reading a paper, first identify the population and design. For cell studies, check whether primary human cells or a cell line were used, how the polysaccharide was purified, whether the particle was soluble, and what stimulus was used for restimulation. For animal studies, identify species and route of administration. In a clinical trial, review the prespecified outcome, sample size, control, participant losses, duration, intention-to-treat or per-protocol analysis, and adverse events. Cytokines, IgA, or cell counts are not equivalent to lower disease incidence, cancer treatment, or a lasting immune effect.
No universal reishi or maitake dose for infection prevention or cancer treatment has been established from comparable clinical trials. Do not stop prescribed therapy or replace it with a mushroom product. If someone is considering a supplement, discuss its exact composition and intended goal with a health professional, and assess effects using a clinically meaningful outcome rather than a general promise of “immune support.”
This narrative scientific review explains the relationship between fungal β-glucan structure, Dectin-1 recognition, experimental trained innate immunity, and human evidence. Primary studies were used to check key claims: structural biochemistry of β-glucans and Dectin-1, cell studies of signalling and trained immunity, animal models, and clinical trials of specific preparations. PubMed records and primary publications were checked on 9 October 2026. This is not a systematic review: a full search of all databases, duplicate study selection, and meta-analysis were not performed.
Where mechanistic and clinical evidence differed, the text preserves differences in substance form, model, and endpoint. Numbers are given only for identifiable human studies; missing or conflicting data were not replaced with assumptions. Laboratory monocyte stimulation, mouse models of central trained immunity, and clinical outcomes from supplements are described separately. This review does not establish a treatment recommendation.
Fungal β-glucans are a chemically and physically heterogeneous family of molecules. β-(1→3) and β-(1→6) linkages, branching, size, and particle form matter to how a ligand contacts Dectin-1 and other receptors. Through Syk and CARD9-dependent pathways, β-glucan can change cellular responses in experiments; epigenetic and metabolic studies provide a plausible mechanism for trained innate responses. But this mechanism does not establish that oral reishi or maitake products reliably prevent infection or improve cancer treatment. Human evidence depends on the specific product, and some trials measured only laboratory markers. The practical point is to compare well-characterized preparations and clinical outcomes, not rely on the broad label “β-glucan.”
No. Source, linkages, branching, molecular size, solubility, and particle form can differ. Findings for one standardized yeast product cannot automatically be applied to reishi or maitake.
It recognizes some β-glucan structures on innate immune cells and can signal through Syk- and CARD9-dependent pathways. The response depends on cell type and ligand form.
It is a changed later response of innate cells after an initial exposure, shown in cell and animal models. It is not antigen-specific lymphocyte memory and does not establish lasting protection after a supplement.
There is no general conclusion for mushroom supplements. One trial of a specific yeast product reported fewer symptomatic colds in a per-protocol analysis, while a small study of another oral β-glucan did not enhance measured innate responses.
The laboratory and small clinical studies discussed here do not establish them as stand-alone cancer treatments. The maitake MDS study was open-label and measured cellular surrogate outcomes; a clinical trial of pharmaceutical lentinan did not improve overall survival.
No. Oral polysaccharides may interact with the gut, but their detailed uptake and systemic transport in people are not established. Trace blood levels and cell-laboratory effects do not prove delivery to bone marrow.
The reviewed trials do not establish a universal dose for infection prevention or cancer treatment. They used different materials and outcomes, so one product’s protocol should not be transferred to another.
Interaction data are insufficient for many products. Discuss the exact product with a clinician when using immunosuppressants, anticoagulants, or glucose-lowering medicines, before surgery, and during pregnancy or breastfeeding.